Cantex and Harvard's Wyss Institute to expand development of Azeliragon

Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.

8 bulk drugs projects commissioned under PLI scheme

The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa

USFDA grants Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis therapy

Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases

Industry needs to ensure quality standards : S Aparna, Union Pharma Secretary

Collaboration in the industry needs to be institutionalised to drive the growth.

Bayer highlights pharma business plans on Media Day

Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)

Biosion appoints Joel Edwards as Chief Business Officer

Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.

Prestige BioPharma’s Tuznue receives EU-GMP certification

Prestige BioPharma’s facility receives EU-GMP certification

The facility will manufacture its Herceptin biosimilar, Tuznue

Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma

The transaction as well as the open offer is expected to be completed by June this year.

Strides receives USFDA approval for Amantadine Hydrochloride capsules

To be marketed by Strides Pharma Inc. in the US market